Dive deeper

Open any topic for the full explanation, tables, clinical checkpoints, and references.

Full-length video Where can I learn more about skin-cancer treatment urgency?

A complete visual guide

Watch the full explanation on YouTube A complete visual review with the supporting clinical context.
What makes skin-cancer treatment more or less urgent?

Urgency Is a Risk Question

“Urgent” is not a diagnosis. It is a judgment about what could change if care is delayed.

A small, sharply defined lower-risk BCC commonly grows locally and rarely spreads. A deeply invasive or rapidly growing cSCC in an immunosuppressed patient has a different risk. Melanoma urgency is shaped by depth, ulceration, stage, and whether the biopsy completely established the microstage.1–5

The useful question is:

What is the longest reasonable interval before the delay could change tumor size, stage, treatment complexity, function, or outcome?

A clinician may not be able to name a precise safe day. The goal is a defined plan, not false precision.

When should I call the treating team promptly?

When to Call Promptly

Contact the treating team promptly if you notice:

  • rapid growth;
  • new or increasing pain;
  • numbness, tingling, weakness, or facial asymmetry;
  • recurrent bleeding or ulceration;
  • a firm or fixed tumor;
  • a new lump in a nearby lymph-node area;
  • threatened vision, eyelid closure, breathing, swallowing, or another function;
  • pathology describing nerve involvement, poor differentiation, substantial depth, invasion beyond fat, lymphovascular invasion, or bone involvement; or
  • a diagnosis occurring during organ-transplant or other significant immune suppression.2,3,5,6

These findings do not prove that the cancer has spread. They identify a pathway where waiting without reassessment carries more consequence.

How does the diagnosis change the timeline?

How Diagnosis Changes the Timeline

Basal cell carcinoma

Most BCC grows locally. Short treatment delay can allow a larger tumor and a larger defect, particularly in high-stakes anatomy, but the consequence varies greatly by subtype, site, recurrence, and health.1,7 Aggressive, recurrent, poorly defined, perineural, very large, or function-threatening BCC belongs on a faster pathway.

Observation may be reasonable for selected frail patients with low-risk BCC when competing illness changes the value of intervention and follow-up is reliable.8 That decision should be explicit and revisited if the tumor changes.

Cutaneous squamous cell carcinoma

cSCC spans a wide spectrum. Lower-risk tumors often permit orderly outpatient scheduling. Higher- and very-high-risk disease can recur, involve nerves, spread to nodes, and threaten disease-specific survival; depth, differentiation, immune suppression, recurrence, perineural symptoms, and rapid growth should accelerate care.2,3,5,6

Melanoma

Melanoma requires prompt, organized review of Breslow thickness, ulceration, margin status, and sampling adequacy. Definitive excision and any sentinel-node decision should be coordinated so that staging information is not lost and the operation follows current guidance.4,9

A short interval to obtain expert pathology review or coordinate a melanoma team may improve the plan. Indefinite delay is different.

SCC in situ and other superficial tumors

SCC in situ and selected superficial BCC often permit more scheduling flexibility than invasive higher-risk disease. The diagnosis must be secure: a superficial sample can miss invasion or a more aggressive component.1,2

What can safely happen while I wait?

What Can Safely Happen While You Wait

Use the interval productively:

  1. Obtain the pathology report and biopsy photograph.
  2. Clarify subtype, depth, differentiation, nerve involvement, ulceration, and sampling limitations.
  3. Arrange dermatopathology review if the diagnosis is rare, ambiguous, or high consequence.
  4. Ask whether imaging or lymph-node evaluation is needed.
  5. Review medicines and medical conditions that affect surgery or radiation.
  6. Choose the appropriate treating clinician and location.
  7. Decide whether a driver, caregiver, staged repair, or other logistics are needed.
  8. Obtain a specific deadline and instructions for changes that should trigger earlier review.

An observational cohort associated longer delays before treatment of keratinocyte carcinoma with larger eventual surgical defects; this does not predict an individual patient's outcome.

What can make the treatment timeline faster?

What Makes the Timeline Faster?

What Makes the Timeline Faster?
PatternUsual responseWhy
Small, well-defined, lower-risk BCC or cSCCTimely scheduled outpatient treatmentA short coordinated interval is usually different from an unsafe delay.
Rapid growth, recurrence, immune suppression, aggressive pathology, pain, or numbnessPrompt escalationThese features can raise recurrence, nerve, nodal, or functional risk.
Melanoma with uncertain microstage or sentinel-node questionPrompt coordinated pathology and surgical planningThe sequence of excision and nodal staging matters.
Palpable node, cranial-nerve symptom, threatened vision, or suspected deep invasionUrgent multidisciplinary assessmentImaging or broader oncologic care may be required before local treatment.

Rapid growth, increasing pain, bleeding, neurologic symptoms, or an enlarging regional node should prompt earlier contact with the treating team.

What does the evidence say about treatment delay?

Evidence by the Numbers

Evidence by the NumbersUrgency follows risk, not the word cancer alone

Urgency follows risk, not the word cancer alone

10,196 cSCCs

Population
Retrospective validation cohort stratified by NCCN risk
Outcome
Five-year disease-specific death was 0.1% in low-risk, 0.5% in high-risk, and 10.5% in very-high-risk cSCC
Time horizon
Five years

What it means: A very-high-risk tumor deserves faster coordination and a more deliberate staging and margin plan than a routine low-risk tumor.

Limitations: These are group outcomes from cSCC and do not create a universal deadline for every patient.

References: 5

Frequently asked questions about treatment urgency

Frequently Asked Questions

Will a few weeks always make my skin cancer worse?

No. The effect depends on diagnosis and risk. A short planned interval may be reasonable for many tumors, while a biologically aggressive or symptomatic cancer deserves faster coordination.

Can delay make the surgery larger?

Yes. Keratinocyte cancers can continue to grow, and longer delay has been associated with larger defects in observational work.7 The magnitude is not predictable for one patient.

Should I go to an emergency department?

Most skin-cancer treatment is not emergency-department care. Emergency evaluation may be appropriate for uncontrolled bleeding, acute neurologic or visual symptoms, severe infection, or another immediate medical problem. Otherwise, contact the treating team promptly.

What if my appointment is farther away than expected?

Ask the clinician who reviewed the pathology whether the interval fits the risk. Request a cancellation list or alternate qualified referral if the delay is not appropriate.

Does “high risk” mean the cancer has spread?

No. It means features are associated with a greater chance of recurrence or spread and may justify more intensive local treatment or staging.

Who reviewed and authored this urgency guide?
Portrait of Dr. Thomas L.H. Hocker

About the Author

Dr. Thomas L.H. Hocker is a Harvard- and Mayo Clinic-trained, triple board-certified dermatologist, Mohs surgeon, and dermatopathologist. He is the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health and an Iron Surgeon lecturer at the American Society for Dermatologic Surgery. His work focuses on Mohs surgery for melanoma, complex and rare skin tumors, and aesthetic reconstruction after skin-cancer treatment. He co-authored the best-selling textbook Review of Dermatology and created Skin Trust to give patients and clinicians free access to clear, current, evidence-based education.

Read Dr. Hocker's background and mission

Dr. Hocker earned his bachelor's degree with honors from Yale University, where he was inducted into Phi Beta Kappa. As a Winston Churchill Scholar, he then studied at the University of Cambridge and earned an M.Phil. in Organic Chemistry. He received his M.D. with honors from Harvard Medical School, where his research focused on melanoma genetics. He completed dermatology residency at Mayo Clinic, a dermatopathology fellowship at the University of Michigan, and a Mohs micrographic and reconstructive surgery fellowship at Mayo Clinic. He is board-certified in Dermatology, Dermatopathology, and Mohs Micrographic Surgery.

Dr. Hocker serves as the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health. He is an internationally invited lecturer and speaker who teaches about Mohs surgery for melanoma, complex and rare tumors, dermatopathology, and aesthetic reconstruction after skin-cancer treatment. He has also been selected as an Iron Surgeon lecturer by the American Society for Dermatologic Surgery. He is the co-author of Review of Dermatology, a best-selling dermatology review textbook, and he continues to teach and mentor medical students, residents, and physicians.

Skin Trust exists because Dr. Hocker believes access to excellent medical knowledge should not depend on geography, wealth, or proximity to a major academic center. After training at several of the world's leading institutions, he sees that education as both a gift and a responsibility: to translate current evidence, expert judgment, and hard-won clinical experience into guidance that patients, families, and clinicians can actually use.

The mission is to increase awareness, reduce avoidable suffering, and give every person equal access to trustworthy, up-to-date information that can help them make the best decisions for their life. Skin Trust also extends Dr. Hocker's lifelong commitment to teaching, writing, and mentoring medical students and residents as they build lives and careers of purpose and service.

For Dr. Hocker, this work is also an expression of faith. He regards the opportunities to learn at Yale, Cambridge, Harvard, Mayo Clinic, and the University of Michigan as blessings from God. Teaching, writing, mentoring, and building Skin Trust are ways to pay those blessings forward in service to patients, learners, and the broader community. His faith is the personal motivation to do this work carefully, generously, and with integrity; it is not a condition of using or benefiting from this free resource.

View Review of Dermatology Read Dr. Hocker's full biography
Where should I go next in the Patient Journey?

Next Steps in the Patient Journey

Continue to the risk and treatment guide that matches your diagnosis.

Continue with the question that fits you now

References for this treatment-urgency guide

References

  1. National Comprehensive Cancer Network. Basal Cell Skin Cancer. Version 2.2026.
  2. National Comprehensive Cancer Network. Squamous Cell Skin Cancer. Updated March 17, 2026.
  3. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines for cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018.
  4. National Comprehensive Cancer Network. Melanoma: Cutaneous. Updated April 17, 2026.
  5. Stevens JS, Murad F, Smile TD, et al. Validation of NCCN cSCC risk stratification. JAMA Dermatol. 2023.
  6. Wysong A. Squamous-cell carcinoma of the skin. N Engl J Med. 2023.
  7. Eide MJ, Weinstock MA, Dufresne RG Jr, et al. Treatment delay and surgical defect size in keratinocyte carcinoma. J Invest Dermatol. 2005. PMID: 15675948.
  8. van Winden MEC, Hetterschijt CR, Bronkhorst EM, et al. Watchful waiting and BCC tumor behavior. JAMA Dermatol. 2021. PMID: 34495284.
  9. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines for primary cutaneous melanoma. J Am Acad Dermatol. 2019. PMID: 30392755.